Polar Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Polar Capital’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-3,084	Closed	-$191K	–	304
2014 Q2	$191K	Buy	3,084 +774	+34%	+$45K	﹤0.01%	263
2014 Q1	$150K	Buy	2,310 +1,279	+124%	+$86.5K	﹤0.01%	266
2013 Q4	$58K	Buy	+1,031	New	+$57.9K	﹤0.01%	266

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Polar Capital's OREX Position: Q3 2014 in Review

Polar Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 3,084 shares — an estimated $191K sold.

Polar Capital first reported a position in OREX in Q4 2013 and held it in 3 quarters. The position peaked at $191K in Q2 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

Polar Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
Polar Capital sold 3,084 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $191K.
Polar Capital first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 3 quarters.
Polar Capital's Orexigen Therapeutics, Inc. position peaked at $191K in Q2 2014.
128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Polar Capital's 13F filing for Q3 2014, filed 13 Nov 2014.